Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension

Alan H. Gradman, Neal R. Cutler, Pamela J. Davis, John A Robbins, Robert J. Weiss, Barry C. Wood

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension. After a 4-week, single-blind placebo baseline period, 707 patients with sitting diastolic blood pressures (BPs) in the range of 95 to 115 mm Hg received placebo, enalapril (5 or 20 mg), felodipine ER (2.5, 5, or 10 mg), or their combinations for an 8-week double-blind treatment period. All doses of enalapril and felodipine ER had a statistically significant (p <0.05) additive effect in reducing both systolic and diastolic BP. The trough to peak ratios for the combinations ranged from 0.63 (enalapril 5 mg-felodipine ER 2.5 mg) to 0.79 (enalapril 20 mg-felodipine ER 10 mg) and were consistent with effective BP control with 1 dose/day. Patients aged ≥65 years demonstrated a greater reduction in diastolic BP. Combinations of enalapril-felodipine ER were associated with less drug-induced peripheral edema (4.1%) compared to felodipine ER monotherapy (10.8%). There were no serious drug-related adverse effects observed during the study. In this trial, the combination of enalapril and felodipine ER effectively lowered BP and was generally well tolerated with an excellent safety profile when used in the treatment of hypertension.

Original languageEnglish (US)
Pages (from-to)431-435
Number of pages5
JournalAmerican Journal of Cardiology
Volume79
Issue number4
StatePublished - Feb 15 1997

Fingerprint

Felodipine
Enalapril
Blood Pressure
Hypertension
Placebos
Safety
Angiotensin-Converting Enzyme Inhibitors
Pharmaceutical Preparations
Blood Vessels
Edema
Calcium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gradman, A. H., Cutler, N. R., Davis, P. J., Robbins, J. A., Weiss, R. J., & Wood, B. C. (1997). Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension. American Journal of Cardiology, 79(4), 431-435.

Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension. / Gradman, Alan H.; Cutler, Neal R.; Davis, Pamela J.; Robbins, John A; Weiss, Robert J.; Wood, Barry C.

In: American Journal of Cardiology, Vol. 79, No. 4, 15.02.1997, p. 431-435.

Research output: Contribution to journalArticle

Gradman, AH, Cutler, NR, Davis, PJ, Robbins, JA, Weiss, RJ & Wood, BC 1997, 'Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension', American Journal of Cardiology, vol. 79, no. 4, pp. 431-435.
Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension. American Journal of Cardiology. 1997 Feb 15;79(4):431-435.
Gradman, Alan H. ; Cutler, Neal R. ; Davis, Pamela J. ; Robbins, John A ; Weiss, Robert J. ; Wood, Barry C. / Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension. In: American Journal of Cardiology. 1997 ; Vol. 79, No. 4. pp. 431-435.
@article{6a7da6359b6d42e8830e4b43a195834b,
title = "Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension",
abstract = "This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension. After a 4-week, single-blind placebo baseline period, 707 patients with sitting diastolic blood pressures (BPs) in the range of 95 to 115 mm Hg received placebo, enalapril (5 or 20 mg), felodipine ER (2.5, 5, or 10 mg), or their combinations for an 8-week double-blind treatment period. All doses of enalapril and felodipine ER had a statistically significant (p <0.05) additive effect in reducing both systolic and diastolic BP. The trough to peak ratios for the combinations ranged from 0.63 (enalapril 5 mg-felodipine ER 2.5 mg) to 0.79 (enalapril 20 mg-felodipine ER 10 mg) and were consistent with effective BP control with 1 dose/day. Patients aged ≥65 years demonstrated a greater reduction in diastolic BP. Combinations of enalapril-felodipine ER were associated with less drug-induced peripheral edema (4.1{\%}) compared to felodipine ER monotherapy (10.8{\%}). There were no serious drug-related adverse effects observed during the study. In this trial, the combination of enalapril and felodipine ER effectively lowered BP and was generally well tolerated with an excellent safety profile when used in the treatment of hypertension.",
author = "Gradman, {Alan H.} and Cutler, {Neal R.} and Davis, {Pamela J.} and Robbins, {John A} and Weiss, {Robert J.} and Wood, {Barry C.}",
year = "1997",
month = "2",
day = "15",
language = "English (US)",
volume = "79",
pages = "431--435",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension

AU - Gradman, Alan H.

AU - Cutler, Neal R.

AU - Davis, Pamela J.

AU - Robbins, John A

AU - Weiss, Robert J.

AU - Wood, Barry C.

PY - 1997/2/15

Y1 - 1997/2/15

N2 - This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension. After a 4-week, single-blind placebo baseline period, 707 patients with sitting diastolic blood pressures (BPs) in the range of 95 to 115 mm Hg received placebo, enalapril (5 or 20 mg), felodipine ER (2.5, 5, or 10 mg), or their combinations for an 8-week double-blind treatment period. All doses of enalapril and felodipine ER had a statistically significant (p <0.05) additive effect in reducing both systolic and diastolic BP. The trough to peak ratios for the combinations ranged from 0.63 (enalapril 5 mg-felodipine ER 2.5 mg) to 0.79 (enalapril 20 mg-felodipine ER 10 mg) and were consistent with effective BP control with 1 dose/day. Patients aged ≥65 years demonstrated a greater reduction in diastolic BP. Combinations of enalapril-felodipine ER were associated with less drug-induced peripheral edema (4.1%) compared to felodipine ER monotherapy (10.8%). There were no serious drug-related adverse effects observed during the study. In this trial, the combination of enalapril and felodipine ER effectively lowered BP and was generally well tolerated with an excellent safety profile when used in the treatment of hypertension.

AB - This multicenter, placebo-controlled, double-blind trial of factorial design evaluated the safety and efficacy of combination treatment with the angiotensin-converting enzyme inhibitor, enalapril, and the vascular selective calcium antagonist felodipine extended release (ER) in patients with essential hypertension. After a 4-week, single-blind placebo baseline period, 707 patients with sitting diastolic blood pressures (BPs) in the range of 95 to 115 mm Hg received placebo, enalapril (5 or 20 mg), felodipine ER (2.5, 5, or 10 mg), or their combinations for an 8-week double-blind treatment period. All doses of enalapril and felodipine ER had a statistically significant (p <0.05) additive effect in reducing both systolic and diastolic BP. The trough to peak ratios for the combinations ranged from 0.63 (enalapril 5 mg-felodipine ER 2.5 mg) to 0.79 (enalapril 20 mg-felodipine ER 10 mg) and were consistent with effective BP control with 1 dose/day. Patients aged ≥65 years demonstrated a greater reduction in diastolic BP. Combinations of enalapril-felodipine ER were associated with less drug-induced peripheral edema (4.1%) compared to felodipine ER monotherapy (10.8%). There were no serious drug-related adverse effects observed during the study. In this trial, the combination of enalapril and felodipine ER effectively lowered BP and was generally well tolerated with an excellent safety profile when used in the treatment of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0031568452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031568452&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 431

EP - 435

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -